Key clinical point: Biologics improved disease activity (DA) in a real-world population of patients with psoriatic arthritis (PsA) in Italy.
Major finding: At 6 months, a substantially high proportion of patients receiving biologics achieved the European league against rheumatism (EULAR) DA Score 28 (71.8%; 95% CI, 66.7%-76.8%), with outcomes being similar with secukinumab (73.4%; 95% CI, 65.8%-81.1%) and tumor necrosis factor-inhibitors (71.9%; 95% CI, 64.9%-78.8%). The responder rate was 68.0% at year 1.
Study details: Findings are from a multicenter, noninterventional, cohort study including 399 patients with PsA, of which 308 were evaluable at 6 months and 297 patients were evaluable at 1 year. Most patients received biologics for ≥6 months.
Disclosures: This study was supported by a grant from Novartis Farma S.p.A. Origgio. Three authors declared being part-time/regular employees of Novartis Farma or MediNeos Observational Research, hired by Novartis Farma. The authors declared receiving honoraria, speaker fees, and/or scientific support from other sources.
Source: Colombo D et al. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: Results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: An ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study. BMC Rheumatol. 2022;6(1):57 (Sep 12). Doi: 10.1186/s41927-022-00284-w.